Man Group PLC Travere Therapeutics, Inc. Transaction History

Man Group PLC

$35.6 Billion
Q4 2024

A detailed history of Man Group PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 88,241 shares of TVTX stock, worth $2.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

88,241

Previous 25,443 246.82%

Holding current value

$2.06 Million

Previous $355,000 332.96%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $857,192 - $1.25 Million	62,798 Added 246.82%	88,241 $1.54 Million
Q3 2024 Nov 14, 2024	SELL	$7.89 - $15.21 $577,697 - $1.11 Million	-73,219 Reduced 74.21%	25,443 $355,000
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $99,619 - $156,814	-18,939 Reduced 16.1%	98,662 $811,000
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $844,375 - $1.15 Million	117,601 New	117,601 $906,000
Q1 2023 May 15, 2023	SELL	$17.82 - $22.89 $49,896 - $64,092	-2,800 Reduced 13.15%	18,500 $416,000
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $51,716 - $73,192	2,800 Added 15.14%	21,300 $447,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $423,835 - $529,655	18,500 New	18,500 $456,000
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $198,930 - $285,095	-9,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $224,295 - $290,700	9,500 New	9,500 $245,000
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $1.26 Million - $1.71 Million	-53,777 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $1.03 Million - $1.5 Million	53,777 New	53,777 $1.47 Million

Others Institutions Holding TVTX

# of Institutions

213

Shares Held

94.1M

Call Options Held

1.2M

Put Options Held

778K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.5B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account